Overview
Tremfya is an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (1)

Coverage Guidelines
Approval will be granted if the member meets the following criteria:
1. Member has a diagnosis of moderate-severe plaque psoriasis AND
2. Member is at least 18 years of age AND
3. Prescriber has provided documentation of ONE of the following:
   a. Inadequate response, adverse reaction, or contraindication to at least TWO conventional therapies in any one of the following combinations (combinations DO NOT have to be used concurrently):
      i. 1 topical agent + 1 systemic agent
      ii. 1 topical agent + 1 phototherapy (required for diagnosis of guttate psoriasis)
      iii. 1 systemic agent + 1 phototherapy
      iv. 2 systemic agents
   b. Contraindication to ALL conventional therapies
      i. Topical agents
      ii. Phototherapy
      iii. Systemic agents
   c. Inadequate response or adverse reaction to ONE biologic DMARD that is FDA-approved for plaque psoriasis
   AND
4. Dosing is appropriate (see appendix)
Continuation of Therapy
Reauthorization will be granted if documentation is submitted indicating a positive response to therapy

Limitations
1. Initial approvals will be granted for 3 months
2. Reauthorizations will be granted for up to 1 year

Appendix

<table>
<thead>
<tr>
<th>Tremfya® (guselkumab)</th>
<th>Plaque Psoriasis:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SQ: 100 mg initially at week 0 and 4; followed by 100 mg every eight weeks</td>
</tr>
</tbody>
</table>

References

Review History
03/01/2018: Implemented
02/20/2019: Reviewed P&T Mtg

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.